141 related articles for article (PubMed ID: 19223643)
1. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
[TBL] [Abstract][Full Text] [Related]
2. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.
Zhou XJ; Garner RC; Nicholson S; Kissling CJ; Mayers D
J Clin Pharmacol; 2009 Dec; 49(12):1408-16. PubMed ID: 19776293
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.
Zala C; St Clair M; Dudas K; Kim J; Lou Y; White S; Piscitelli S; Dumont E; Pietropaolo K; Zhou XJ; Mayers D
Antimicrob Agents Chemother; 2012 May; 56(5):2570-5. PubMed ID: 22314532
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
[TBL] [Abstract][Full Text] [Related]
5. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers.
Eiznhamer DA; Creagh T; Ruckle JL; Tolbert DT; Giltner J; Dutta B; Flavin MT; Jenta T; Xu ZQ
HIV Clin Trials; 2002; 3(6):435-50. PubMed ID: 12501127
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
Dousson C; Alexandre FR; Amador A; Bonaric S; Bot S; Caillet C; Convard T; da Costa D; Lioure MP; Roland A; Rosinovsky E; Maldonado S; Parsy C; Trochet C; Storer R; Stewart A; Wang J; Mayes BA; Musiu C; Poddesu B; Vargiu L; Liuzzi M; Moussa A; Jakubik J; Hubbard L; Seifer M; Standring D
J Med Chem; 2016 Mar; 59(5):1891-8. PubMed ID: 26804933
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
13. A review of the pharmacokinetics of abacavir.
Yuen GJ; Weller S; Pakes GE
Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
[TBL] [Abstract][Full Text] [Related]
15. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
[TBL] [Abstract][Full Text] [Related]
18. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
19. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
J Clin Pharmacol; 2001 Oct; 41(10):1098-105. PubMed ID: 11583478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]